Jade Biosciences (NASDAQ:JBIO – Get Free Report) issued its earnings results on Friday. The company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.31, FiscalAI reports.
Jade Biosciences Stock Performance
Shares of JBIO stock traded up $0.27 during trading hours on Friday, hitting $16.14. The company had a trading volume of 593,498 shares, compared to its average volume of 829,735. Jade Biosciences has a 12 month low of $9.60 and a 12 month high of $28.00. The firm has a market capitalization of $1.03 billion, a price-to-earnings ratio of -8.41 and a beta of 1.81. The firm’s fifty day moving average is $15.32 and its 200 day moving average is $18.14.
Hedge Funds Weigh In On Jade Biosciences
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Entropy Technologies LP bought a new stake in Jade Biosciences in the third quarter valued at $145,000. Engineers Gate Manager LP bought a new position in shares of Jade Biosciences during the second quarter valued at $503,000. Profund Advisors LLC lifted its holdings in shares of Jade Biosciences by 21.5% during the third quarter. Profund Advisors LLC now owns 26,008 shares of the company’s stock valued at $365,000 after acquiring an additional 4,596 shares during the period. Quantinno Capital Management LP boosted its stake in shares of Jade Biosciences by 3.6% in the 1st quarter. Quantinno Capital Management LP now owns 30,551 shares of the company’s stock valued at $429,000 after purchasing an additional 1,059 shares in the last quarter. Finally, Bank of America Corp DE boosted its stake in shares of Jade Biosciences by 2.9% in the 1st quarter. Bank of America Corp DE now owns 38,598 shares of the company’s stock valued at $542,000 after purchasing an additional 1,086 shares in the last quarter.
Analysts Set New Price Targets
A number of equities research analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $55.00 price target on shares of Jade Biosciences in a research note on Thursday, October 1st. Jefferies Financial Group restated a “buy” rating and issued a $48.00 price objective on shares of Jade Biosciences in a research note on Tuesday, August 11th. BTIG Research restated a “buy” rating and issued a $77.00 price objective on shares of Jade Biosciences in a research note on Tuesday, October 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Jade Biosciences in a report on Friday, September 11th. Finally, Wall Street Zen upgraded shares of Jade Biosciences from a “strong sell” rating to a “sell” rating in a research report on Saturday. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $51.75.
View Our Latest Analysis on JBIO
Jade Biosciences Company Profile
Jade Biosciences is a biotechnology company developing antibody-based treatments for autoimmune diseases. Its research focuses on targets involved in immune activity that can contribute to chronic disease. The company’s lead program, JADE101, is an antibody designed to block APRIL, a protein involved in the production of antibodies. Jade is developing the candidate for IgA nephropathy, a kidney disease in which abnormal IgA antibodies can damage the kidneys. Jade’s pipeline is focused on potential therapies for autoimmune conditions.
Read More
- Five stocks we like better than Jade Biosciences
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Jade Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jade Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
